Samsung Bioepis, G2GBio partner on long-acting obesity drug development
Story summarySamsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement with Korean biotech G2GBio to develop long-acting obesity treatments, the companies said Monday.
Read at The Korea HeraldOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.